### <u>AMENDMENT</u>

#### In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

#### 1-4. (Cancelled)

- 5. (Currently amended) A carrier protein according to claim 4, that comprises a P23TT, P32TT, P21TT, PfCs PFT3, P30TT, P2TT, HBVnc, HA influenza haemagglutinin (HA), HbsAg and MT influenza matrix (MT) CD4+ T cell epitope.
- 6. (Currently amended) A carrier protein according to elaim 4 claim 5, that comprises a P23TT, P32TT, P21TT, PfCs PFT3, P30TT, P2TT, HBVnc, HA, HbsAg, MT and hsp70 CD4+ T cell epitope.

# 7-12. (Cancelled)

- 13. (Currently amended) A carrier protein according to claim 11 37, wherein the polysaccharide is from any one of the following organisms: *S. pneumoniae*, *N. meningitidis*, *S. aureus*, *Klebsiella*, or *S. typhimurium*.
- 14. (Currently amended) A carrier protein according to claim 11 37, wherein the polysaccharide is conjugated to the carrier protein by a covalent linkage.

Dkt No. PP00362.102 USSN: 09/674,183

**PATENT** 

15. (Currently amended) A carrier protein according to claim 11 37, wherein the polysaccharide is conjugated to the carrier protein by reductive amination.

16. (Currently amended) A carrier protein according to claim 44 37, wherein between two and ten carrier protein molecules are present for each polysaccharide molecule.

## 17-32. (Cancelled)

- 33. (Currently amended) A <u>The</u> carrier protein according to claim 5, wherein the CD4+ T cell epitopes are human CD4+ T cell epitopes.
- 34. (Currently amended) A <u>The</u> carrier protein according to claim 6, wherein the CD4+ T cell epitopes are human CD4+ T cell epitopes.
- 35. (Currently amended) A <u>The</u> carrier protein according to claim 5 in an oligomeric form.
- 36. (Currently amended) A <u>The</u> carrier protein according to claim 6 in an oligomeric form.
- 37. (Currently amended) A <u>The</u> carrier protein according to claim 5, conjugated to a polysaccharide.
- 38. (Currently amended) A <u>The</u> carrier protein according to claim 6, conjugated to a polysaccharide.

Dkt No. PP00362.102 USSN: 09/674,183

**PATENT** 

39. (Currently amended) A <u>The</u> carrier protein according to claim 37, wherein the polysaccharide is an *Haemophilus influenzae* type B polysaccharide.

- 40. (Currently amended) A <u>The</u> carrier protein according to claim 38, wherein the polysaccharide is an *Haemophilus influenzae* type B polysaccharide.
- 41. (Previously presented) A vaccine comprising the carrier protein according to claim 5.
- 42. (Previously presented) A vaccine comprising the carrier protein according to claim 6.
- 43. (Previously presented) A vaccine comprising the carrier protein according to claim 39.
- 44. (Previously presented) A vaccine comprising the carrier protein according to claim 40.